Shopping Cart
Remove All
Your shopping cart is currently empty
CBL 0100 free base is an HIV-1 transcription inhibitor that blocks HIV-1 replication and reactivation in vitro and in ex vivo models. It targets the chromatin-associated transcription (FACT) complex, reducing the occupancy of RNA Polymerase II and FACT in the HIV-1 promoter region, and can be used as a latency-reversing agent (LRA) in cART therapy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $333 | - | In Stock | |
| 5 mg | $790 | - | In Stock | |
| 10 mg | $1,120 | - | In Stock | |
| 25 mg | $1,670 | - | In Stock | |
| 50 mg | $2,230 | - | In Stock | |
| 100 mg | $2,950 | - | In Stock |
| Description | CBL 0100 free base is an HIV-1 transcription inhibitor that blocks HIV-1 replication and reactivation in vitro and in ex vivo models. It targets the chromatin-associated transcription (FACT) complex, reducing the occupancy of RNA Polymerase II and FACT in the HIV-1 promoter region, and can be used as a latency-reversing agent (LRA) in cART therapy. |
| In vitro | Treatment of J-LAT A1 and A2 cells with CBL 0100 free base (0.1 μM) resulted in a decrease in both the GFP+ cell population and the GFP mean fluorescence intensity (MFI) in J-LAT A1 and A2 cells without any cytotoxicity.[1] |
| Synonyms | Curaxin 100, CBL0100 free base, CBL 0100 free base, 6-[2-(Diethylamino)ethyl]-10,11-dihydro-1H-dicyclopenta[c,g]carbazole-3,9(2H,6H)-dione (ACI), 1H-Dicyclopenta[c,g]carbazole-3,9(2H,6H)-dione, 6-[2-(diethylamino)ethyl]-10,11-dihydro- (ACI) |
| Molecular Weight | 374.48 |
| Formula | C24H26N2O2 |
| Cas No. | 1197996-83-0 |
| Smiles | O=C1C2=CC=C3C(C=4C(=CC=C5C(=O)CCC54)N3CCN(CC)CC)=C2CC1 |
| Color | White |
| Appearance | Solid |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.